Endoscopic Retrograde Cholangiopancreatography (ERCP) Market Analysis and Forecast to 2031: By Product (Endoscope, Endotherapy Device, Visualization Systems, Energy Devices, Others), Procedure (Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation,

Endoscopic Retrograde Cholangiopancreatography (ERCP) Market Analysis and Forecast to 2031: By Product (Endoscope, Endotherapy Device, Visualization Systems, Energy Devices, Others), Procedure (Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation, Pancreatic Sphincterotomy, Pancreatic Duct Stenting, Pancreatic Duct Dilatation), End User (Hospitals, Ambulatory Surgery Centers & Clinics, Others), and Region

The global endoscopic retrograde cholangiopancreatography was valued at USD 1.5 billion in 2021 and it is anticipated to grow up to USD 2.9 billion by 2031, at a CAGR of 6.5% during the forecast period.

In order to diagnose and treat disorders of the bile and pancreatic ducts, endoscopic retrograde cholangiopancreatography (ERCP) combines endoscopy with x-ray technology. The use of precut sphincterotomy during endoscopic retrograde cholangiopancreatography (ERCP) may increase the likelihood that a cannulation will be successful, but it is associated with an increased risk of post-ERCP pancreatitis. For patients with difficult biliary access, applying precut sphincterotomy involving sphincterotomes sooner rather than later may reduce this risk.

Global Endoscopic Retrograde Cholangiopancreatography Market Scope and Report Structure

Market Trends and Drivers

The incidence of cancer is rising globally today. Cancer was the second-leading cause of death worldwide in 2018, accounting for 9.6 million fatalities, according to the WHO. The American Cancer Society predicts that in 2022, there will be roughly 41,260 new instances of liver cancer and intrahepatic bile duct cancer detected in the US. Since 1980, the incidence of liver cancer has more than tripled, while the fatality rate has more than doubled. About 60,430 new cases of the pancreatic disease were identified in the US in 2021.

Market Restraints and Challenges

The high cost of ERCP tools and procedures is one of the most important market restraints. A duodenoscope typically sells for between USD 31,500 (Non-HD) and USD 37,000. (HD). This is not good because of the expensive cost and the lengthy operation. Additionally, according to an interview with a market specialist for ERCP, one of the main barriers to the process being widely accessible and inexpensive for many small-scale end users who serve a sizable population, particularly in developing nations, is its cost.

Global Endoscopic Cholangiopancreatography Market Segmental Overview

The report analyses global endoscopic cholangiopancreatography market based on product, procedure, end users, and region.

Global Endoscopic Cholangiopancreatography Market by Product

Based on product, it is segmented into endoscopes, endotherapy devices, visualization systems, energy devices, and others. The endotherapy devices segment is likely to dominate the market during the forecast period. The key factors such as the growth of minimally invasive surgeries coupled with the increasing prevalence of gastrointestinal conditions are boosting the growth of the market.

Global Endoscopic Cholangiopancreatography Market by Procedure

Based on procedure, it is segmented into biliary sphincterotomy, biliary stenting, biliary dilatation, pancreatic sphincterotomy, pancreatic duct stenting, and pancreatic duct dilatation. The biliary sphincterotomy segment is likely to account for the majority of the market share during the forecast period. The key factors such as increasing pancreatic duct and bile duct stones coupled with the increase in the geriatric population are boosting the growth of the market.

Global Endoscopic Cholangiopancreatography Market by End User

Based on end user, it is segmented into hospitals, ambulatory surgery centers & clinics, and other end users. The hospital end user segment is likely to dominate the market during the forecast period. The key factors such as rising incidences of cancer coupled with increasing investments, funds, and grants by governments and healthcare organizations to improve endoscopy research are boosting the growth of the market.

Geographical Analysis of Global Endoscopic Cholangiopancreatography Market

Region-wise, it is studied across North America, Europe, Asia Pacific, and the Rest of the World. The Asia Pacific and Latin America regions are considered as the fastest growing regions of the global endoscopic cholangiopancreatography market. The healthcare industry in Brazil has undergone tremendous changes, making the nation one of the world's most promising and alluring marketplaces. Governments in various Latin American nations place a strong emphasis on enhancing their respective healthcare systems. Along with this, the advancement of the healthcare infrastructure in nations like China and India to better serve large populations of patients with critical illnesses like cancer and tumors, as well as Japan's well-developed healthcare system with universal health insurance coverage, are propelling the market in these areas forward quickly.

Major Players in the global endoscopic cholangiopancreatography Market

COVID-19 Impact

A global crisis has been caused by the COVID-19 epidemic. Patients and surgeons who frequent hospitals for various treatments are more likely to contract COVID-19. A reduction in device-based therapies like ERCP was brought about by the suspension of the majority of gastrointestinal procedures. In Germany's largest hospitals, between 40 and 50 percent of endoscopic procedures were postponed. The COVID-19 pandemic drastically decreased ERCP procedures, according to a study. Restrictions on endoscopic services in the UK and other countries also decreased the success rate.

Recent Developments

• January 2022, Cook Medical launched an endoscopic clipping device, named Instinct Plus, which is compatible through a duodenoscope, has application for defect closure, anchoring procedures and prophylactic clipping in the gastrointestinal (GI) tract.
• May 2021, Steris Plc, acquired Cantel Medical which enabled Steris Healthcare to expand its product portfolio and cater to customer across the globe.
• March 2021, Fujifilm Holdings Corporation acquired Hitachi, Ltd. Company’s diagnostic imaging-related business, adding to the former’s stronghold in the healthcare business.
• October 2020, Olympus Corporation launched two endotherapy devices, Stone Master V and Vortic Catch V, to increase the efficiency in bile duct stone management and retrieval for ERCP and announced a partnership with Holberg to develop and distribute the Autoscore algorithm.

Frequently Asked QuestionsQ1. How big is the Endoscopic Retrograde Cholangiopancreatography market?Ans. The global Endoscopic Retrograde Cholangiopancreatography market size was USD 1.5 Billion in 2021 and is anticipated to reach USD 2.9 Billion in 2031, growing at a rate of 6.5% from 2022 to 2031.Q2. What is the Endoscopic Retrograde Cholangiopancreatography market growth rate?Ans. The growth rate of the Endoscopic Retrograde Cholangiopancreatography market is 6.5% from 2022 to 2031.Q3. Which region holds a major market share for the Endoscopic Retrograde Cholangiopancreatography market?Ans. North America holds a major market share of the Endoscopic Retrograde Cholangiopancreatography market in 2021.Q4. Which segment accounted for the largest Endoscopic Retrograde Cholangiopancreatography market share?Ans. By end user, the hospitals segment accounted for the largest Endoscopic Retrograde Cholangiopancreatography market share.Q5. Who are the key players in the Endoscopic Retrograde Cholangiopancreatography market?Q6. What are the factors driving the Endoscopic Retrograde Cholangiopancreatography market growth?Ans. The major factors driving the growth of the market are the increasing preference for minimally invasive surgeries.Q7. What are the key growth strategies of Endoscopic Retrograde Cholangiopancreatography market players?Ans. The key growth strategies of Endoscopic Retrograde Cholangiopancreatography market players are product launch and product approval.Q8. Which region will provide more business opportunities for the Endoscopic Retrograde Cholangiopancreatography market during the forecast period?Ans. The Asia-Pacific region will provide more business opportunities for the Endoscopic Retrograde Cholangiopancreatography market during the forecast period.

Please Note: This report will be delivered by publisher within 3-4 business days of order confirmation.